Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.34 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376899 | 0.78 | NUDT1 (0.32) | — | |
| SCHEMBL30125106 | 0.77 | — | — | |
| SCHEMBL1153496 | 0.77 | — | — | |
| SCHEMBL19073173 | 0.77 | NOS3 (0.31) | — | |
| SCHEMBL10048540 | 0.77 | SCN9A (0.47) | RXRAGRIN1GRIN2BKMT2AMEN1 | |
| SCHEMBL8958798 | 0.77 | SCN9A (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL7049033 | 0.76 | — | — | |
| SCHEMBL8154440 | 0.74 | MAPK8 (0.41) | EDNRBEDNRARXRAGRIN1GRIN2B | |
| SCHEMBL10385800 | 0.74 | CYP1A2 (0.41) | RXRAGRIN1GRIN2BALOX15SMN1; SMN2 | |
| SCHEMBL25097150 | 0.72 | GAA (0.43) | EDNRBEDNRARXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9481705-B2 | Modular radiochemistry synthesis system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-12 | — | — | US | disclosed |
| US-9211520-B2 | Modular radiochemistry synthesis system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150329583-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | ENERGY, UNITED STATES DEPARTMENT OF | 2015-11-19 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8951480-B2 | Modular radiochemistry synthesis system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-10 | — | — | US | disclosed |
| US-8877733-B2 | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8765933-B2 | Asynthesis of β-nucleosides | PHARMAESSENTIA CORP. (TW) | 2014-07-01 | — | — | US | disclosed |
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120259106-A1 | ASYNTHESIS OF B-NUCLEOSIDES | PHARMAESSENTIA CORP. (TW) | 2012-10-11 | — | — | US | disclosed |
| US-8193339-B2 | Synthesis of β-nucleosides | PHARMAESSENTIA CORP. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-20090124797-A1 | NOVEL SYNTHESIS OF BETA-NUCLEOSIDES | PHARMAESSENTIA CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | EDNRB 1354/4885EDNRA 2063/4885RXRA 3187/4885 |
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, TYMP | EDNRB 2725/4885EDNRA 2538/4885RXRA 1898/4885 |
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | RAD18, MVD, USP18 | EDNRB 4079/4885EDNRA 3605/4885RXRA 3686/4885 |
| US-20120259106-A1 | ASYNTHESIS OF B-NUCLEOSIDES | ATIC, DPYD, DUT | EDNRB 1821/4885EDNRA 2487/4885RXRA 2098/4885 |
| US-20150329583-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | RAD18, MVD, USP18 | EDNRB 4079/4885EDNRA 3605/4885RXRA 3686/4885 |
| US-20090124797-A1 | NOVEL SYNTHESIS OF BETA-NUCLEOSIDES | DUT, DCTD, UMPS | EDNRB 3301/4885EDNRA 3533/4885RXRA 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.